GLP-1 Receptor Agonists & Metabolic Research Compounds

The incretin system is a central signaling axis in metabolic research. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are enteroendocrine hormones released postprandially from the gut that act through distinct G-protein-coupled receptors. Synthetic peptide analogs of these endogenous hormones have become foundational laboratory tools for studying receptor pharmacology, insulin secretion dynamics, and energy balance regulation in controlled in vitro and animal model systems.

Dual agonism describes peptides engineered to activate more than one receptor simultaneously. Tirzepatide (CAS 2023788-19-2) is a dual GIP/GLP-1 receptor agonist whose research interest centers on the hypothesis that concurrent activation of both incretin receptors may elicit greater downstream signaling in laboratory models than selective GLP-1 agonism alone. In experimental settings, dual agonists are studied for their receptor binding affinity, plasma half-life extension, and pharmacokinetic behavior.

Triple agonism extends this logic to glucagon receptor co-activation. Retatrutide (CAS 2381089-83-2) is a triple agonist engineered to bind GLP-1, GIP, and glucagon receptors. The glucagon receptor arm is of research interest because glucagon signaling is implicated in hepatic glucose output and lipolytic drive in adipose tissue, distinct from the incretin axes. The combination of incretin and glucagon signaling in a single molecule is an active area of preclinical investigation.

Beyond incretin agonists, this research category includes lipolytic peptides such as AOD-9604, a C-terminal fragment (residues 177-191) of human growth hormone studied for its hypothesized lipolytic signaling in adipose tissue models, and lipotropic blends (Lipo-C) combining methionine, inositol, and choline for lipid-metabolism pathway research. All compounds are supplied for laboratory and scientific research use only and are not for human consumption.